S. Korea Report Accuses Generics Makers Of Overpricing
This article was originally published in PharmAsia News
South Korea's drug authority accused the country's drug makers of inflating the prices of their generic drugs. The Korea Development Institute said in a report that some drug makers sell generics for prices close to the price of the brand-name drug even though the generic makers experienced no development costs. In some cases, it said, the generic price is as close as 80 percent of the brand price. A KDI researcher attributed some of the pricing to government controls that set prices based on hospital negotiations with drug makers who give kickbacks to the hospitals. The reported noted that 80 percent of drugs sold in South Korea are generics. (Click here for more
You may also be interested in...
The FDA must report to the House Appropriations Committee on any work toward defining “natural” cosmetics and on the health effects of talc, asbestos and lead in cosmetic products. The committee’s 2021 FDA spending bill report also cites concerns about skin-lightening products containing “dangerous levels of mercury and hydroquinone.”
Verrica got a complete response rather than approval for its drug/device combo for molluscum, but says the FDA only needs additional information on product changes for safe usage by clinicians.
COVID-19 Consumer Health Market: Germ-Blocking Nasal Spray, 99.99% Effective Sanitizer, ‘Mask’ To Moisturize Hands
Sensory Cloud’s small study showed FEND nasal solution cut by 99% exhalation of bioaerosol to block COVID-19. Global BioProtect’s hand sanitizer with proprietary antibacterial technology eliminates 45 bacteria, fungi and virus. Trilogy Labs’ solution replenishes moisture in hands irritated by sanitizers.